Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2014; 20(39): 14172-14184
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14172
Published online Oct 21, 2014. doi: 10.3748/wjg.v20.i39.14172
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome
Carly E Kelley, Ann J Brown, Tracy L Setji, Department of Medicine, Division of Endocrinology, Duke University Medical Center, Durham, NC 27710, United States
Anna Mae Diehl, Department of Medicine, Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, United States
Author contributions: Kelley CE, Brown AJ, Diehl AM and Setji TL all contributed to the writing of this paper.
Correspondence to: Tracy L Setji, MD, MHS, Department of Medicine, Division of Endocrinology, Duke University Medical Center, Box 3222, 201 Trent Drive, Durham, NC 27710, United States. tracy.setji@duke.edu
Telephone: +1-919-6135120 Fax: +1-919-6135503
Received: February 28, 2014
Revised: April 11, 2014
Accepted: April 30, 2014
Published online: October 21, 2014
Processing time: 233 Days and 18.7 Hours
Revised: April 11, 2014
Accepted: April 30, 2014
Published online: October 21, 2014
Processing time: 233 Days and 18.7 Hours
Core Tip
Core tip: Nonalcoholic fatty liver disease (NAFLD) is a relatively common condition that can progress to nonalcoholic steatohepatitis (NASH) and even cirrhosis. Polycystic ovary syndrome (PCOS) has recently been recognized as a potential risk factor for NAFLD/NASH. Although screening for NAFLD is problematic, clinicians need to be aware that some patients with PCOS may develop significant liver disease, and at a much younger age than is typical. Identifying PCOS patients at risk for NAFLD, and early intervention in these patients, is needed to help prevent long term and serious complications of fatty liver.